Trial Profile
A phase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2014
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 15 Jan 2014 Planned number of patients changed from 19 to 51, as reported by ClinicalTrials.gov record
- 15 Jan 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record
- 06 Mar 2008 Status changed from completed to in progress, reported by ClinicalTrials.gov.